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Receptor-mediated apoptosis proceeds via two pathways: one requiring only a cascade of
initiator and effector caspases (type I behavior) and the second requiring an initiator–effector
caspase cascade and mitochondrial outer membrane permeabilization (type II behavior).
Here, we investigate factors controlling type I versus II phenotypes by performing Lyapunov
exponent analysis of an ODE-based model of cell death. The resulting phase diagrams predict
that the ratio of XIAP to pro-caspase-3 concentrations plays a key regulatory role: type I
behavior predominates when the ratio is low and type II behavior when the ratio is high.
Cell-to-cell variability in phenotype is observed when the ratio is close to the type I versus II
boundary. By positioning multiple tumor cell lines on the phase diagram we conﬁrm these
predictions. We also extend phase space analysis to mutations affecting the rate of caspase-3
ubiquitylation by XIAP, predicting and showing that such mutations abolish all-or-none
control over activation of effector caspases. Thus, phase diagrams derived from Lyapunov
exponent analysis represent a means to study multi-factorial control over a complex biochemical
pathway.
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Introduction
In mammalian cells, once the commitment to apoptosis has
been made, caspase-mediated protein degradation must
proceed to completion lest cells survive with damaged
genomes. At a biochemical level, this involves all-or-none
activation of potent effector caspases (caspase-3 and caspase-
7). Extrinsic apoptosis, induced by extracellular death ligands
such as Fas ligand (FasL), tumor necrosis factor (TNF), or
TRAIL (TNF-related apoptosis-inducing ligand), begins
with assembly of death inducing signaling complexes (DISCs)
on receptor intracellular tails. Initiator pro-caspases (caspase-
8 and caspase-10) dimerize at the DISC, leading to activation
and concomitant cleavage of inhibitory pro-domains. In
type I cells, a cascade of activated initiator (caspase-8/10)
and effector (caspase-3/7) caspases is sufﬁcient to generate a
lethal level of caspase activity and mitochondrial outer
membrane permeabilization (MOMP) is not required. In
cells that exhibit type II behavior, active caspase-8/10 still
cleaves pro-caspase-3/7 but MOMP is required for death
(Scafﬁdi et al, 1998). Type I and type II phenotypes are
generally assumed to be mutually exclusive: most epithelial
cells exhibit a type II phenotype but some immune cells
and cells having a ‘mesenchymal’ expression proﬁle exhibit
a type I phenotype (Algeciras-Schimnich et al, 2003).
Identifying factors that control type I versus II apoptosis
is not only relevant to understanding regulation of
extrinsic apoptosis in immune editing, tumor surveillance
and cancer therapy but also exempliﬁes the more general
challenge of determining how different cell types use distinct
but overlapping pathways to control essential physiological
processes.
MOMP, the event controlling apoptosis in type II cells, is
triggered by caspase-8/10-mediated cleavage of Bid into its
active form (tBid) followed by tBid-mediated changes in
the conformation and activity of Bak and Bax (Letai, 2008).
Active Bak/Bax molecules are able to self-assemble into
pores in the mitochondrial outer membrane but assembly
is inhibited by anti-apoptotic members of the Bcl2 protein
family. When levels of active Bak/Bax exceed those
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ing Smac/DIABLO and cytochrome c to translocate into the
cytosol (Letai, 2008). Smac-mediated inhibition of XIAP,
a protein that negatively regulates active caspase-3/7, and
apoptosome-mediated cleavage of pro-caspase-3/7 generates
a burst of active effector caspase able to cleave essential
cellular substrates and cause cell death. Experiments with
membrane-bound and soluble FasL suggest that a key
distinction between type I and type II cells is the rate of
DISC assembly and the consequent efﬁciency of pro-caspase-
8/10 activation (Algeciras-Schimnich et al, 2003). In type I
cells, caspase-8/10 is activated sufﬁciently rapidly to
cleave pro-caspase-3/7 and trigger death (Scafﬁdi et al, 1998;
Barnhart et al, 2003). In type II cells, the generation of
active caspase-8/10 is proposed to be less efﬁcient and
MOMP is therefore necessary to amplify a weak initiator
caspase signal (Barnhart et al, 2003). However, other studies
suggest an important role for XIAP in determining the balance
between type I and type II death (Eissing et al, 2004; Jost et al,
2009).
Using a mass-action model developed in our laboratory to
describe key biochemical steps in extrinsic apoptosis
(EARM1.4; Box 1; Albeck et al, 2008a,b; Spencer et al,
2009), we searched for factors inﬂuencing type I and type II
behaviors. This involved identifying factors that determined
whether or not MOMP was required for efﬁcient effector
caspase activation. Such an analysis can be performed in a
straightforward manner using the method of direct ﬁnite-time
Lyapunov exponent analysis (DLEs; Box 2; Aldridge et al,
2006b; Rateitschak and Wolkenhauer, 2010). DLEs measure
the inﬂuence of changes in initial protein concentrations on
the future state of a model; in the case of EARM1.4, we
examinedtimescalesdeterminedexperimentallytoberelevant
tocaspaseactivationinTRAIL-treatedcells(B8h).WhenDLE
analysis was used to compute a six-dimensional phase
diagram of type I or II phenotypes, a distinct boundary
(a separatrix) was observed to cut across multiple dimensions
in concentration phase space (separatrices are described in
Box 2). The shape of the separatrix implied that control over
type I versus II phenotypes was multi-factorial: DISC activity
and ligand levels were determinative for some protein
concentrations whereas XIAP and caspase-3 levels were
important across the entire sampled space. To test these
predictions experimentally, we placed four tumor cell lines on
the DLE landscape, focusing on two-dimensional slices
corresponding to the [XIAP]:[caspase-3] ratio. We found that
the separatrix correctly predicted whether a cell line was type I
or type II. In the case of T47D cells, the [XIAP]:[caspase-3]
ratio placed them close to the separatrix and experiments
conﬁrmed a mixed type I and type II phenotype. We also
extendedouranalysistochangesinrateconstants,focusingon
mutations that reduced the rate of XIAP-mediated ubiquityla-
tion of caspase-3. When this reaction was blocked modeling
predicted, and experiments conﬁrmed, a phenotype distinct
from either type I or II behavior in which snap-action
control over cleavage of effector caspase substrates was lost.
Based on these observations, we propose that DLE-based
phase diagrams will prove generally useful in understanding
multi-factorial control of cellular biochemistry in different
cell types.
Results
A DLE-based phase map predicts the
[XIAP]:[caspase-3] ratio to control type I versus II
phenotypes
To determine which proteins control the choice between type I
and type II phenotypes during apoptosis, we computed DLEs
for a previously published ordinary differential equation
model describing key reactions in TRAIL-mediated extrinsic
apoptosis (EARM1.4; see Box 1). Bcl2 over-expression is the
standard method for distinguishing type I and type II cells
experimentally (Scafﬁdi et al, 1998): type I cells over-
expressing Bcl2 die when exposed to death ligand but type II
cells do not. Simulations were therefore performed in the
presence of sufﬁcient Bcl2 to block MOMP (this level was
conservatively set to a value lower than the level of Bcl2
present in cell lines stably transfected with Bcl2 over-
expression constructs; Supplementary Figure S1A). DLE
analysis was performed by allowing the initial concentrations
(i.e. concentrations prevailing prior to TRAIL exposure) of six
proteins (receptor, ligand, caspase-3, caspase-6, caspase-8,
and XIAP) to vary in discrete steps above and below nominal
values (see Box 1 and Supplementary Table SII). The
magnitude of the variation and the step size were determined
by the sensitivity of cleaved effector caspase substrate (cEC-S)
levels to changes in protein concentrations: greater sensitivity
mandated smaller steps and biochemical plausibility set the
upper limit at 10
6molecules/cell (higher than the average
concentration of any apoptotic regulator we have measured in
any cell line). DLE analysis generated a multi-dimensional
phase diagram relating initial protein concentrations to cell
fate 8h after TRAIL addition. Quantitative immunoblotting of
cell extracts relative to recombinant protein standards was
used to estimate the absolute concentrations of apoptotic
regulators in tumor cell lines and ﬂow cytometry was used to
estimate cell-to-cell variability within a single line (Box 1
Table). Speciﬁc cell lines were then placed on the landscape
of initial conditions (Figure 1A and B; Supplementary
Figure S1). No model adjustment or reﬁtting was performed
when cell lines were added to the landscape; only the
concentrations of proteins were changed to match measured
values.
As in any phase diagram, the most interesting regions of
phase space are those in which small changes in parameter
values cause large changes in outcome; in Lyapunov exponent
analysis,thesegiverisetoseparatriceshavinghighDLEvalues
(Box 2). A separatrix was clearly apparent in two-dimensional
slices of phase space representing [XIAP] versus [caspase-3]
(in the following discussion ‘caspase-8’ or ‘caspase-3’ refers to
the inactive pro-forms of the enzymes; in the few cases where
we mean the active form, we speciﬁcally refer to active or
cleaved caspase). Simulation predicted that cells having a high
ratio of [XIAP]:[caspase-3] would survive TRAIL exposure in
the presence of over-expressed Bcl2, thereby exhibiting type II
behavior. However, cells with a low [XIAP]:[caspase-3] ratio
should die, thereby exhibiting type I behavior (Figure 1A and
B). We observed that SKW6.4 B-cell lymphoma and HCT116
colon carcinoma lines, which show prototypical type I and
type II behaviors,respectively (Scafﬁdi et al, 1998; Ozoren and
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Box 1 Figure EARM1.4 network diagram. Schematic adapted from Albeck et al (2008b).
The mass-action model used in the current paper, extrinsic apoptosis reaction model (EARM1.4), is closely related to previously published models that have been
validated using live- and ﬁxed-cell imaging, ﬂow cytometry of caspase substrates, and biochemical analysis of normal and RNAi-treated HeLa cells (Albeck et al,
2008a,b;Spencer etal,2009). Modelcompartments are assumed tobewell mixed andproteintranslocation ismodeledasanelementary reaction inwhich proteins
move between three compartments (cell surface, cytoplasm, and mitochondrial inter-membrane space). As in Spencer et al (2009), EARM1.4 includes protein
synthesis (ks) and degradation (kdeg) reactions but some rate constant have been changed to improve goodness of ﬁt (red arrows in Box 1 Figure summarize
changes relative to Albeck et al (2008b); see Supplementary Tables SI–SIII for lists of model reactions and initial concentration and rate parameter values). Except
for active caspase-3, the half-lives of proteins species are assumed to be 24h, an approximation that is satisfactory because the model is relatively insensitive to
changes in these rates. EARM1.4 successfully reproduces initiator and effector caspase dynamics in multiple cell types across a range of ligand doses and under
various conditions of RNAi-mediated protein depletion (Albeck et al, 2008a,b). EARM1.4 encompasses proteins activated by binding of TRAIL to DR4/5 receptors
that ultimately cause cleavage of effector caspase substrates and cell death. EARM1.4 focuses on reactions regulating MOMP and caspase-3 activity; it does not
model the formation of DISCs or the activation of caspase-8/10 in detail. However, two mechanisms negatively regulating caspase-8 are included in simpliﬁed form:
competitivebindingofFLIPandpro-caspase-8totheDISCandreversible inhibitionofprocessedcaspase-8byBar.Thislevelofdetailissufﬁcienttoexploretherole
of TRAIL, TRAIL receptor, and caspase-8/10 concentrations on downstream events, but it does not capture key events in receptor oligomerization. Two pathways
link initiator and effector caspases. In the direct pathway, the sole mechanism required in type I cells, active caspase-8 cleaves pro-caspase-3; this activates the
enzyme and allows it to cleave PARP. In the model, a positive feedback between effector and initiator caspases is mediated by caspase-6. Even though it is not yet
completely clear how strong this feedback is in cells or whether proteins other than caspase-6 are involved, variation in caspase-6 levels in EARM1.4 can still be
regarded as a means to alter the strength of a feedback mechanism that involves multiple proteins. Recent work suggests that this mechanism for caspase-8/10
activationisinefﬁcient(Oberstetal,2010;Wurstleetal,2010)andfeedbackisthereforemodeledasbeingweakinEARM1.4.IntypeIIcells,MOMP,whichalsolinks
initiator and effector caspases, is required for caspase-3 activation. MOMP-dependent translocation of cytochrome c from mitochondria to the cytosol leads to
Box 1 Modeling receptor-mediated apoptosis.
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2004),layonoppositesidesofthecomputedseparatrix(Figure
1B and C; Supplementary Figure S1), consistent with the
known behavior of these cells. SKW6.4 cells occupied a
position in phase space at which even very high XIAP
concentrations would not be expected to yield type II death
(Figure 1B and C). We tested this prediction experimentally by
showing that even 20-fold XIAP over-expression did not alter
the fraction of cells that died in response to TRAIL exposure
(Supplementary Figure S1D). In contrast, HCT116 cells
occupied a position in phase space at which deletion of XIAP
should switch them from type II to type I.
Loss of XIAP in type II HCT116 cells converts them
to a type I phenotype
To explore the function of XIAP in HCT116 cells, we used
retroviral infection to stably over-express Bcl2 in parental
HCT116 cells and in a congenic line in which XIAP had been
deleted by gene targeting (hereafter OE-Bcl2/DXIAP HCT116
cells; see Table I for a glossary of cellular and molecular
reagents; Cummins et al, 2004). Quantitative immunoblotting
conﬁrmed that Bcl2 concentrations were similar in OE-Bcl2
and OE-Bcl2/DXIAP HCT116 lines (Figure 2A; Supplementary
Figure S1A). Cells were then treated with TRAIL, FasL, or TNF
and the extent of apoptosis monitored using three comple-
mentary methods: ﬂow cytometry with antibodies speciﬁc
for the cleaved form of the caspase-3/7 substrate PARP
(cPARP; hereafter referred to as cEC-S), live-cell microscopy
of cells expressing ﬂuorescent reporters of initiator or
effector caspases (IC-RP or EC-RP; Albeck et al, 2008a), and
clonogenic survival assays. Although each assay has distinct
strengths and weaknesses (Galluzzi et al, 2009), in our hands
all three assays yielded quantitatively similar estimates
of the probability and timing of extrinsic cell death (Albeck
et al, 2008a) and corresponded well with other measures
of apoptosis such as annexin V staining (Gaudet et al,
2005). Experiments were initially performed in the presence
of the protein synthesis inhibitor cycloheximide (CHX),
which simpliﬁed modeling because TRAIL-induced protein
synthesis could be largely ignored (see Albeck et al, 2008b),
but experiments were repeated in the absence of CHX. The
results were similar (see below), and we conclude that
our ﬁndings are not unduly inﬂuenced by low-dose CHX
treatment.
As predicted by simulation, TRAIL, FasL, or TNF exposure
killed 80–95% of WT, DXIAP, and OE-BCL2/DXIAP HCT116
apoptosome formationandactivationofcaspase-9,anotherinitiator caspasecapable ofcleaving pro-caspase-3.MOMPalsocausescytosolic translocationofSmac,
whichbindstotheeffectorcaspaseinhibitorXIAP,therebyinactivatingitandrelievinginhibitionofcaspase-3activity.Theanalysisinthispapershowsthattheratioof
caspase-3 to XIAP levels is a major determinant of type Iversus II behavior: when the ratio is low, XIAP is able to hold processed caspase-3 incheck prior to MOMP.
When the ratio is high, sufﬁcient active caspase-3 accumulates to kill cells in the absence of MOMP. Many species in EARM1.4 are devoted to the regulation of
MOMP but the process is nonetheless represented in a highly simpliﬁed manner. The pathway leading to MOMP begins with cleavage of Bid by active caspase-8 to
form tBid. tBid can either be sequestered in the cytoplasm by an Mcl-1-like protein or bind to and activate Bax. Active Bax multimerizes and translocates to the
mitochondrial outer membrane where it is inhibited by Bcl2 but once active, membrane-bound Bax levels exceed those of Bcl2, MOMP occurs, leading to
translocationofSmacandcytochromectothecytosol,asdescribedabove.EARM1.4 doesnotattempttomodelthe fullcomplexityofthe Bcl2proteinfamily,instead
representing all Bcl2 family activators by Bid,all anti-apoptotic familymembersby Bcl2 and Mcl-1 andall pore forming proteins byBax. Nonetheless, a goodmatch is
observedbetweensimulationsandsingle-celldataonMOMPdynamicsoverawiderangeofconditions(Albecketal,2008a,b).Valuesfortheinitialconcentrationsof
proteins in the model for which validated antibodies are available were determined by quantitative immunoblotting of extracts from HCT116 cells (see Box 1 Figure,
purple, and Supplementary Table SII) and then adjusted for other cell lines using the ratios listed in Table I; for simplicity, all cells were modeled as having the same
cell volume. When modeling the effectof deleting the RINGdomain of XIAP,the rate constant forthe ubiquitylation ofcaspase-3 by XIAP(kc8)was setto zero.When
cycloheximide was included in an experiment, synthesis terms in the corresponding simulations were set to 15% of their nominal values (Supplementary Table SII;
Ceccarini and Eagle, 1976). Degradation rates were set assuming a half-life of 24h as in Spencer et al (2009) except that the XIAP-independent rate of degradation
of active caspase-3 (kr14) was set to ﬁvefold higher to account for the observed instability of caspase-3 in HCT116DXIAP cells (BBA and PKS, unpublished data).
Box 1 Continued
Box 1 Table Relative initial protein concentration as measured by quantitative immunoblotting of whole-cell lysates from HCT116, SKW6.3, and T47D cells
HCT116 SKW6.4 T47D
XIAP 1.00±0.12 0.38±0.11 0.64±0.05
Caspase-3 1.00±0.32 8.86±2.83 3.51±0.13
PARP 1.00±0.00 1.12±0.35 1.04±0.02
Caspase-8 1.00±0.02 0.93±0.34 0.48±0.07
Caspase-6 1.00±0.17 0.67±0.07 2.25±0.67
Bax 1.00±0.14 9.83±3.43 1.42±0.12
Bcl-xl 1.00±0.71 0.58±0.26 1.38±0.04
Mcl-1 1.00±0.87 1.25±0.85 4.64±2.00
Bid 1.00±0.01 1.87±0.34 1.34±0.07
Smac 1.00±0.03 1.77±0.16 1.39±0.03
Flip 1.00±0.48 5.91±2.64  0.48±0.06
Bcl2
a  0.05±0.01 1.00±0.20 0.26±0.22
aNormalized to SKW6.4 values because endogenous Bcl2 is not detectable in HCT116 cells.
All concentrations are normalized to values observed in HCT116 (with the exception of Bcl2, which is normalized to SKW6.4 levels).
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Box 2 Figure Multi-dimensional views of the phase space and a type I versus II DLE separatrix. DLE analysis is inherently multi-dimensional and phase diagrams
can be visualized in different subspaces. On the left, three three-dimensional views are shown of a separatrix cutting through phase space for [XIAP]0, [caspase-3]0,
and [caspase-8]0 at different concentrations of TRAIL. The two-dimensional phase diagrams on the right represent slices of the three-dimensional matrix under the
baseline ligand condition (as indicated by the projected red and green outlines).
The goal of this paper was to determine whether measured differences in protein concentrations could explain how cell lines sharing a common set of
apoptotic regulators respond differently to death ligands. In some contexts, such a question could be approached using bifurcation analysis but thisi s
challenging with a model as large as EARM1.4. More importantly, model steady states (as used for bifurcation analysis) are not reﬂective of the transient signals
that determines whether cells live or die (see also Aldridge et al, 2006b). Lyapunov exponents are a simple means to compute the effects on model output arising
fromchangesininitialproteinconcentrations. Becauseeachproteinpresentatt¼0givesrisetomultiple speciesthatdifferinintracellularlocalization,extentofpost-
translational modiﬁcation, incorporation into molecular complexes, etc., variation in initial protein concentrations generates unintuitive and complex changes
in cellular biochemistry that vary from one cell type to the next. The critical dynamical variable in the current work is the level of cEC-S (species 23 ‘cPARP’ in
EARM1.4); accumulation ofcEC-Sisassumed to reﬂect commitment todeath (althoughthisis notnecessarily trueincelllines such asSKW6.4;see textfor details).
We represent the ﬁndings of our analyses using ‘phase space diagrams’ that depict outcomes across arange of protein concentrationsobserved in actual tumor cell
lines. This approach assumes that rate constants and other critical model parameters remain the same across these cell lines. An exception to this rule involves the
analysisofHCT116cellscarryingXIAPDRING;inthiscase,weassumedthattherateofXIAP-mediatedubiquitylationofcleavedcaspase-3waszero(i.e.kc8¼0).In
principle,itwouldbepossibletocomputeaphasediagram,orparameter-spacediagram,forallratesinEARM1.4,butwehavenotyetimplementedthealgorithmsto
dothisefﬁciently. Apriori weexpectsomedifferences ininitialprotein concentrations tohaveamajorimpactonmodel outcomeandotherstohaveasmaller impact.
Box 2 Model analysis using Lyapunov exponents.
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(as assayed in the presence of CHX; Figure 2A and B). Bcl2
over-expression in DXIAP HCT116 cells phenocopied Bcl2
over-expression in OE-Bcl2 SKW6.4 cells (which are naturally
type I): nearly 100% of OE-Bcl2 SKW6.4 cells died in response
to TRAIL or FasL within 6h of ligand exposure (SKW6.4 cells
do not respond by apoptosis to TNF, although they do express
TNFR1 and TNFR2 (Grellet al, 1994) (Figure 2A and B). When
we repeated experiments in the absence of CHX, we obtained
similar results except in the case of clonogenic survival assays
for TRAIL-treated SKW6.4 cells. While a similar fraction of
TRAIL-treated SKW6.4 and OE-Bcl2 SKW6.4 cells were
positive for cIC-S and cEC-S, over-expression of Bcl2 increased
the fraction of SKW6.4 cells that survived TRAIL exposure as
assessed by clonogenic assays, seemingly contrary to their
designation as type I cells (Supplementary Figure S4). Maas
etal(2010)havealsoobservedthatblockingMOMPinSKW6.4
cells makes them less sensitive to TRAIL in clonogenic assays.
We conclude that while EARM1.4 correctly predicts whether
effector caspases are activated in TRAIL-treated SKW6.4 and
HCT116 in the presence and absence of Bcl2 over-expression,
the model is unable to predict the effect of Bcl2 on SKW6.4
survival. Factors unaccounted for in EARM1.4 must control
whetherSKW6.4cellsactuallyliveordieinresponsetoTRAIL.
However, with respect to comparing models and experiments,
effector caspase activation is the key variable in our analysis.
The analysis of HCT116 cells described above makes three
assumptions: (i) that comparison of parental and DXIAP
HCT116 cells is not confounded by secondary mutations; (ii)
that Bcl2 levels in DXIAP HCT116 cells are as high in DXIAPas
in parental HCT116 cells and therefore sufﬁcient to block
MOMP in both cell lines; and (iii) that OE-Bcl2/DXIAP HCT116
cells,likethetypeIIparentalcells,undergorapidandcomplete
effector caspase activation. The ﬁrst concern arises because,
like most cancer cell lines, HCT116 cells are genetically
unstable (LeBlanc et al, 2002). We therefore asked whether
To capture the magnitude of the deviation at a discrete point in time, we compute the multi-dimensional difference between model trajectories arising from
neighboring sets of initial conditions. We quantify this difference by computing a DLE (Equation 1).
DLEðt; x0Þ¼log lmax
qx t ðÞ
qx0
   T qx t ðÞ
qx0
    ! "#
ð1Þ
where DLE(t, x0) is the exponent at time t and x and x0 are vectors that describe the concentrations of model species at time t and t¼0, respectively. lmax is the
maximum eigenvalue of the matrix. DLEs were computed over a grid of initial conditions whose range was chosen based on observed protein concentrationsi n
tumor cell lines, thereby generating a multi-dimensional matrix of DLEs. The most informative regions of the matrix are those with high DLE values, which denote
regions in which small changes in initial conditions result in dramatic changes in model output. Contiguous high DLE values deﬁne separatrices, membrane-like
surfaces that separate regions of parameter space giving rise to different cEC-S dynamics. Separatrices are analogous to boundary layers in a physical phase
diagram, for example betweenliquid,solid, andgas phasesof waterover arange ofvalues for temperature andpressure.Inthe current work, weseek todistinguish
typeIandtypeIIphenotypesinextrinsicapoptosisandthereforeperformsimulationswithBcl2levelssetatalevelsufﬁcientlyhightoblockMOMP(thenominalvalue
for [Bcl2]0 in HCT116 cells is 2 10
4mol/cell; over-expression was modeled as [Bcl2]0¼2 10
5mol/cell). Initial conditions resulting in type I phenotypes were
deﬁned as those in which simulated ﬁnal cEC-S levels were similar in the presence and absence of Bcl2 over-expression; conditions resulting in type II phenotypes
where those in which Bcl2 over-expression blocked cEC-S accumulation. Based on preliminary analysis with a coarse grid, we concentrated on detailed DLE
analysis of six model species. This gave rise to a six-dimensional matrix but, for clarity, the ﬁgures in this paper represent two-dimensional projections. Different cell
lines were placed on these projections based on measuring protein levels by quantitative immunoblotting (Box 1 Table; Supplementary Figure S1) with cell-to-cell
variability estimated by ﬂow cytometry (Box 2 Table). Cell-to-cell variability wasdenoted on the phase diagrams byrepresenting initial protein concentrations ineach
cell line as an ellipsoid (Figure 1B). Proteins other than those analyzed here also vary from one cell line to the next but the apparent success of DLE analysis
suggests that these differences are not major determinants of extrinsic apoptosis in the cell lines we have studied, under our experimental conditions (alternatively,
co-variation inotherdeterminantsmayeffectivelycancelout theireffects).Nonetheless,weexpectthatthe levelsofmanyadditional proteinswillcontributetoTRAIL
sensitivity; it will be possible to analyze these proteins using updated models and DLE phase diagrams with additional dimensions. The idea of analyzing dynamical
systems with respect to their states at a future point in time has recently re-emerged as an important technique in diverse areas of natural science. For example,
methods fundamentally similar to Lyapunov exponent analysis have been used to study the structure of ﬂuid ﬂow in the waters of Monterey Bay and other complex
habitats. The ‘Lagrangrian coherent structures’ calculated using Lyapunov exponents deﬁne boundaries between currents that specify where pollutants will collect,
exemplifying the wide applicability of DLE-style analysis (Coulliette et al, 2007).
Box 2 Continued.
Box 2 Table Coefﬁcients of variation (CV) for caspase-3 and XIAP as measured by ﬂow cytometry for population of cells tightly gated for size and granularity
Cell line Caspase-3 CV XIAP CV
HCT116 0.32±0.07 0.52±0.03
OE-Bcl2 HCT116 0.31±0.09 0.51±0.01
DXIAP HCT116 0.32±0.05 NA
OE-Bcl2/DXIAP HCT116 0.30±0.08 NA
SKW6.4 0.31±0.02 0.42±0.07
OE-Bcl2 SKW6.4 0.32±0.05 0.51±0.06
T47D 0.25±0.06 0.53±0.04
OE-Bcl2 T47D 0.27±0.05 0.55±0.08
Error is estimated by the standard deviation across nine to ﬁfteen independent samples.
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phenotypically. Conducting this complementation experiment
was complicated by the well known difﬁculty of stably over-
expressing full-length XIAP in cells (Silke et al, 2005).
Transient transfection with XIAP-expressing plasmids is
effective but has the secondary effect of sensitizing cells to
extrinsic cell death. If this sensitization is taken into account,
the complementation results were as expected: 95% of OE-
Bcl2/DXIAP HCT116 cells transfected with a plasmid expres-
sing mCherry alone (CHY) were dead 6h after TRAIL
exposure, whereas expression of mCherry-XIAP (CHY-XIAP)
at levels that approximated those in the parental lines (as
measured by ﬂow cytometry; Supplementary Figure S5A),
reduced the level of apoptosis to that of control CHY-
expressing OE-Bcl2 HCT116 cells (B30%; Figure 2C); more-
over, at higher CHY-XIAP levels, even fewer cells died
Table I Cellular and molecular reagents
Name Description Reference
HCT116 cells HCT 116 human colon carcinoma cells, parental
DXIAP HCT116 cells HCT 116 human colon carcinoma cells, with XIAP gene knockout Cummins et al (2004)
OE-Bcl2 HCT116 cells HCT 116 human colon carcinoma cells, stably over-expressing Bcl2 This study
OE-Bcl2/DXIAP HCT116 cells HCT 116 human colon carcinoma cells, with XIAP gene knockout and stably
over-expressing Bcl2
This study
SKW6.4 cells SKW6.4 human B lymphoma cells
OE-Bcl2 SKW6.4 cells SKW6.4 human B lymphoma cells, stably over-expressing Bcl2 This study
T47D cells T47D human breast carcinoma cells
OE-Bcl2 T47D cells T47D human breast carcinoma cells, stably over-expressing Bcl2 This study
CHY mCherry
CHY-XIAP Fusion of mCherry at the N-terminus of full-length XIAP This study
CHY-XIAPDRING Fusion of mCherry at the N-terminus of XIAP with a deletion of the RING
domain (a.a. 437–497)
This study
IC-RP FRET-based initiator caspase reporter Albeck et al (2008a)
EC-RP FRET-based effector caspase reporter Albeck et al (2008a)
cEC-S Cleaved effector caspase substrates This study
cIC-S Cleaved initiator caspase substrates This study
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Figure 1 A DLE phase diagram predicts that XIAP deletion in HCT116 cells switches them from type II to type I. (A) Dynamics. Simulation of EC substrate cleavage
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cells exhibit a type I apoptosis phenotype because of XIAP
deletion, not secondary mutations.
To determine whether Bcl2 was expressed in DXIAP HCT116
cells at levels sufﬁcient to block MOMP, we assayed for
mitochondrial permeabilization in TRAIL-treated cells. It is
important to note that the distinguishing feature of type I cells
is not that mitochondria remain intact following apoptosis,
but rather that MOMP happens after effector caspases are
activated making MOMPa consequence rather than a cause of
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Maas et al, 2010). HCT116 cells were exposed to 50ng/ml
TRAIL and then ﬁxed and stained with anti-cytochrome c
antibodies to measure MOMP and anti-cEC-S antibodies to
monitor effector caspase activity. After a 1h TRAIL treatment,
when the fraction of cEC-S-positive cells was B50%, 97% of
these cells had cytoplasmic cytochrome c, as expected for type
II cells (Figure 3). In contrast, 80% of cEC-S-positive OE-Bcl2/
DXIAP HCT116 cells exhibited mitochondrial cytochrome c,a s
expected for type I cells. Some OE-Bcl2/DXIAP HCT116 cells
were positive for both cytochrome c translocation and cEC-S
but this does not necessarily indicate type II behavior because
caspase-3/7 can trigger MOMP late in the process of killing
type I cells (Ricci et al, 2004). We interpret these data as
showing that Bcl2 is over-expressed at a sufﬁciently high level
to block MOMP prior to caspase-3/7 activation in most if not
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DXIAP HCT116 cell line we observethat only 20% of cells with
high cEC-S levels also exhibited a staining pattern in which
cytochrome c is mitochondrial (Figure 3A). Thus, when Bcl2
is present at normal levels in DXIAP HCT116 cells, they
preferentially die using an MOMP-dependent pathway
whereas when Bcl2 is over-expressed they can still die, but
use a MOMP-independent pathway.
Apoptosis in both type I DXIAP HCT116 and type II
parental HCT116 cells involves rapid and complete
cleavage of effector caspase substrates
Under normal conditions, apoptosis in type II cells is an all-or-
none process in which cleavage of effector caspase substrates,
once initiated, proceeds rapidly to completion (Tyas et al,
2000; Vaughan et al, 2002). Is this also true in SKW6.4 and OE-
Bcl2/DXIAP HCT116 cells? Live-cell imaging of TRAIL-treated
OE-Bcl2 SKW6.4 cells transfected with a construct that
measures effector caspase activity (EC-RP; Albeck et al,
2008a) revealed a preponderance of the switch-like, all-or-
none behavior previously described for type II apoptosis in
HeLa cells (Figure 4A). Live-cell imaging conﬁrmed similarly
rapid and complete EC-RPcleavage in nearly all TRAIL-treated
WT, DXIAP and OE-Bcl2/DXIAP HCT116 cells (Figure 4B;
Supplementary Figure S2) and in all cases complete EC-RP
cleavage was concomitant with morphological manifestations
of cell death (not shown). Thus, TRAIL-mediated apoptosis in
OE-Bcl2/DXIAP HCT116 cells is distinct from the half-dead
state created when XIAP levels are reduced by RNAi in Bcl2
over-expressing HeLa cells (Albeck et al, 2008a); in that case
fractionalactivationofeffectorcaspasesisobservedandonlya
subset of cells die.
We have previously shown that apoptosis in type II HeLa
cells involves an extended pre-MOMP delay in which initiator
but not effector caspases are active (Albeck et al, 2008a). The
delay is most easily visualized in two-dimensional ﬂow
cytometry plots in which the horizontal axis corresponds to
caspase-3 cleavage (cIC-S; a measure of initiator caspase
activity), and the vertical axis corresponds to PARP cleavage
(cEC-S; a measureof effectorcaspase activity (see Albeck et al,
2008aforadetailedcomparisonofﬂowcytometryandlive-cell
imagingassays)).OnehourafterTRAIL addition,HCT116cells
had shifted from the lower left to the lower right quadrant
of the plot, representing accumulation of cells in a pre-MOMP
delay state with initiator caspases active and effector caspases
inactive. By 6h, cells shifted to the upper right quadrant,
representing a state in which both initiator and effector
caspases were active, at which point cells died (Figure 5A,
blue and red arrows). As expected, 90–95% of OE-Bcl2
HCT116 cells accumulated in the lower right quadrant without
evidence of effector caspase activity or death (Figure 5A). In
contrast, TRAIL-treated DXIAP and OE-Bcl2/DXIAP HCT116
cells jumped directly from the lower left to the upper right
quadrants (Figure 5A, orangearrow), conﬁrming model-based
predictions that they would die without delay in a pre-MOMP
state. For SKW6.4 cells (which do express some XIAP), we
observe some delay in progression to death—little caspase
activity is observed 1h after treatment—but ﬂow cytometry
data at subsequent times suggest that initiator and effector
caspases are activated simultaneously, as they are in DXIAP
and OE-Bcl2/DXIAP HCT116 cells (Figure 5B, 6h). In addition,
some SKW6.4 and OE-Bcl2 SKW6.4 cells were found in the
upper left quadrant, suggesting that even relatively low
activation of caspase-3 can trigger signiﬁcant cleavage of
effector caspase substrate in some cells (Figure 5B, orange
bars).
Increasing XIAP levels results in graded
transitions from type I to type II apoptosis
and ultimately to TRAIL resistance
The DLE analysis in Figure 1 was performed over the range of
XIAPconcentrations that naturallyoccur in tumorcell lines we
have studied. However, it is possible to over-express XIAP to
signiﬁcantly higher levels and EARM1.4 predicts that this
should block apoptosis in cells such as HCT116 that have
intermediate levels of caspase-3 (a prediction previously made
by Rehm et al (2006) in the context of HeLa cells). Thus, as
levels of ectopically expressed XIAP in DXIAP HCT116 cells
increase from zero through the concentration found in
parental cells (B3 10
4molecules/cell) to a very high level
(B6 10
5molecules/cell), we should ﬁrst observe a type I
phenotype, then a type II phenotype, and then TRAIL
resistance (cell survival in the absence of Bcl2 over-expres-
sion). To test this prediction, variable levels of CHY-XIAP or
CHY alone were expressed in DXIAP and OE-Bcl2/DXIAP
HCT116 cells and responses to TRAIL were monitored by ﬂow
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Supplementary Figure S5). Accounting for the sensitizing
effects of transfection itself (Figures 2C and 6A), we observed
DXIAP and OE-Bcl2/DXIAP HCT116 cells to be equally
sensitive to TRAIL at very low CHY-XIAP levels, as predicted
for a type I phenotype (Figure 6A and B, green region) but as
CHY-XIAPapproachedwild-typelevels(Figure6AandB,black
arrows), a type II phenotype came to predominate (Figure 6B,
blue region); at yet higher CHY-XIAP concentrations, both OE-
Bcl2/DXIAP and DXIAP HCT116 cells were protected from
TRAIL (Figure 6A and B; gray region). Notably, the transition
from type I to II phenotypes was sufﬁciently gradual that the
two phenotypes co-existed over a range of XIAP expression
levels, as predicted from DLE analysis.
0h 1h 6h
IC off EC off IC on EC off IC on EC on
01234 01234
0
1
2
3
4
0
1
2
3
4
100
0
100
0
%
 
o
f
 
c
e
l
l
s
c
E
C
-
S
 
(
l
o
g
1
0
)
01234
W
T
 
X
I
A
P
Δ
X
I
A
P
%
 
o
f
 
c
e
l
l
s
c
E
C
-
S
 
(
l
o
g
1
0
)
cIC-S (log10) cIC-S (log10) cIC-S (log10)
0
1
2
3
4
A
B
0h 1h 6h
01234 0123401234
S
K
W
6
.
4
01234 01234 01234
cIC-S (log10) cIC-S(log10) cIC-S (log10)
0h 1h 6h
01234 01234 01234
0h 1h 6h
100
0
WT Bcl2 OE-Bcl2
WT Bcl2 OE-Bcl2
cIC-S (log10) cIC-S (log10) cIC-S (log10) cIC-S (log10) cIC-S(log10) cIC-S (log10)
IC off EC off IC on EC off IC on EC on IC low EC on
%
 
o
f
 
c
e
l
l
s
c
E
C
-
S
 
(
l
o
g
1
0
)
IC and EC substrate cleavage in HCT116-derived cells
IC and EC substrate cleavage in SKW6.4-derived cells
Figure5 XIAPdeletion inHCT116 cellsleads toloss ofthe pre-MOMP delay. Two-dimensionalﬂowcytometry of HCT116(A)andSKW6.4 (B)celllines withdifferent
genotypesfollowingexposureto50ng/mlTRAIL þ 2.5mg/mlofCHXfor0–6h,asindicated.Thexaxisrepresentslevelsofinitiatorcaspasesubstratecleavage(cIC-S;
asdeterminedusinganantibodyspeciﬁcforcleavedcaspase-3)andtheyaxisrepresentseffectorcaspasesubstratecleavage(asdeterminedusingacPARPantibody).
Bar plots above show percentages of cells with inactive initiator and effector caspases (green), active initiator and inactive effector caspases (blue), and active initiator
and effector caspases (red) based on the gating denoted with colored dashed lines in (A, upper left). SKW6.4 have an additional population with low initiator caspase
activityand high effector caspaseactivity (orange bars) denoted byorangedashed lines in(B,left). ForOE-Bcl2 HCT116 cells(A,upper right),lightbars represent data
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a mix of type I and type II behaviors
To determine if type I and type II phenotypes might also co-
exist incell populationsnotsubjectedto geneticmanipulation,
we used immunoblotting to identify cell lines that straddled
the separatrix in the [XIAP] versus [caspase-3] phase space
(Figure 7A; Supplementary Figure S1; Box 1 Table). T47D
human breast carcinoma cells have this property and have
previously been reported to be type I based on ligand
sensitivity but to cluster with type II cell lines by transcrip-
tionalproﬁling(Algeciras-Schimnichetal,2003).Weobserved
that over-expression of Bcl2 in T47D cells protected only
B50% from either TRAIL- or FasL-mediated apoptosis (Figure
7B and C). One explanation for this result is that survivors
have higher levels of Bcl2 than dying cells (hypothesis H1 in
Figure 7D). Alternatively, the difference between dying cells
and survivors could reﬂect another difference, such as the
[XIAP]:[caspase-3] ratio (hypothesis H2). Because Bcl2 levels
cannot be reliably measured in dying cells, we used ﬂow
cytometry to compare the concentration of Bcl2 in surviving
cells with that of the starting cell population. No signiﬁcant
difference was observed over the 6h period in which the
fraction of dying cells increase from 0 to B75% (Figure 7D).
These data argue that Bcl2 levels were similar in dying and
surviving cells and thus that some cells required MOMP for
deathand othersdidnot(i.e. H1is correct andH2is wrong).In
support of this idea, immunoﬂuorescence of TRAIL-treated
OE-Bcl2 T47D cells provided clear evidence of EC substrate
cleavage in the absence of MOMP: at least 20% of cEC-S-
positive cells were MOMP negative (Figure 7E). From these
dataweconclude that a fractionof T47D cellsindeed exhibited
a type I phenotype whereas others exhibited a type II
phenotype and required MOMP for death. In preliminary
experiments, we have observed similar behavior in MCF10A
cells,animmortalizedlineofhumanbreastepithelialcellsthat
also straddles the separatrix (D Flusberg, SG, and PKS,
unpublished data).
Multi-factorial control over type I versus II behavior
The experiments described above focus on the [XIAP]:[cas-
pase-3]plane in phase space but our DLE analysiscoversa six-
dimensionalspace.Whenweexaminedsuccessiveslicesofthe
[XIAP]:[caspase-3] plane, varying ligand, receptor, or caspase-
8 concentrations, we observed that as these increased the
position of the separatrix swung downward (toward the
[XIAP] axis) effectively reducing the size of the type II region
(Figure 8A). When we exposed T47D and OE-Bcl2 T47D cells
toTRAILovera12-foldrangeofconcentrations,weobserveda
ﬁvefold increase in the fraction of cells exhibiting a type I
phenotype between low and high doses of TRAIL (Figure 8B).
Thus, the DLE-based phase space appears to correctly predict
at least one other variable regulating type I versus II death.
Moreover,theobservationthattypeIdeathisfavoredathigher
ligand doses is consistent with previous data suggesting the
importance of FasL dose and oligomeric state in controlling
type I fate (Scafﬁdi et al, 1998, 1999b; Schmitz et al, 1999;
Algeciras-Schimnich et al, 2003; Barnhart et al, 2003; Rudner
et al, 2005), although EARM1.4 is not yet sufﬁciently detailed
to compute directly the impact of ligand oligomerization.
Extending phase space analysis to rate constants
We sought to extend our analysis of changes in protein
concentrations to changes in activity that arise from mutation.
XIAP inhibits caspase-3/7 through two distinct mechanisms:
one involving competitive inhibition of caspase-3/7 via
binding of XIAP to the caspase catalytic cleft with an afﬁnity
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cells in OE-Bcl2/DXIAP HCT116 cells from those of DXIAP cells and delineate type I, type II, and apoptosis-resistant regions. Source data is available for this ﬁgure in
the Supplementary Information.
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promotes active caspase-3/7 ubiquitylation and proteosome-
mediated protein degradation (Yang et al, 2000; Suzuki et al,
2001). This second mechanism is regulated by the E3 ubiquitin
ligase activity of XIAP, and it can be blocked by deleting or
mutating the XIAP RING domain without affecting binding of
XIAP to the caspase-3/7 catalytic site (Yang et al, 2000).
Modeling suggests that XIAP-mediated caspase-3 degradation
is important for maintaining a pre-MOMP delay in type II cells
(Albeck et al, 2008a). This prediction is consistent with data
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Figure 7 Individual T47D cells can exhibit either a type I or type II phenotype. (A) Phase-space diagram. Ovals representing variation in [XIAP] and [caspase-3] in
HCT116, T47D, and SKW6.4 cells (as measured by ﬂow cytometry) are mapped onto the phase diagram. (B) Time courses of EC substrate cleavage in T47D cells
having Bcl2 at normal (WT, blue lines) or over-expressed levels (OE-Bcl2, orange lines) following exposure to TRAIL (50ng/ml), FasL (100ng/ml), or TNF (100ng/ml) in
the presence of 2.5mg/ml of CHX (responses to CHX or TRAIL alone are shown in Supplementary Figures S3 and S4). Percentages of cells positive for EC substrate
cleavage were determined by ﬂow cytometry. Bar plots to the right show Bcl2 expression in each cell line, relative to WT SKW6.4 (set to 1, see Figure 2A and
Supplementary Figure S1). Error bars report the standard deviation of biological triplicates from one representative experiment. (C) Survival. Clonogenic assay of WT
and OE-Bcl2 T47D cells following 6h of TRAIL treatment, percentages were obtained by normalizing to CHX alone control. Average numbers of colonies are indicated
abovethegraph(TRAIL-treated/control).Errorbarsreportthestandarddeviationofbiologicaltriplicatesfromonerepresentativeexperiment.(D)Bcl-2levelsinsurviving
cells. Schematic showing two possible hypotheses (H1 and H2) to explain why only a subset of T47D cells are protected from death ligand by Bcl2 over-expression.
Assuming an untreated population in which Bcl2 levels vary (indicated with different shades of orange) it is possible that only cells with high Bcl2 levels survive TRAIL
treatment (upper model, H1); alternatively, cell survival might be determined by other, unknown, factors such that Bcl2 levels in survivors end up similar to those in the
untreated cell population (lower model, H2). Bar plots show the percentages of cells that are negative for EC substrate cleavage (lower panel, left) and mean Bcl2
expressionlevelsinthesecells(lowerpanel,right),asmeasuredbyﬂowcytometryinparentalT47Dcells(blue)andinOE-Bcl2T47DcellspriortoTRAILtreatment(red)
and following 50ng/ml TRAIL þ 2.5mg/ml of CHX exposure for 1–6h (orange; right). Error bars report the standard deviation of biological triplicates from one
representative experiment, the same trends were observed in multiple experiments. (E) Fixed-cell images of WT (top) and OE-Bcl2 (bottom) T47D cells stained for EC
substrate cleavage and cytochrome c 3.5h after 50ng/ml TRAIL þ 2.5mg/ml of CHX addition (scale bar¼20mm). Arrowheads (cyan) denote cells positive for both EC
substrate cleavage and cytoplasmic translocation of cytochrome c and asterisks (yellow) denote cells positive for EC substrate cleavage but having cytochrome c
restricted to mitochondria. Bar plots report the percentages of EC substrate cleavage positive cells where cytochrome c is cytoplasmic (blue) or mitochondrial (yellow).
Error bars report the standard deviation of biological triplicates from three to ﬁve wells, counting B150–700cells/well (see Materials and methods). Source data is
available for this ﬁgure in the Supplementary Information.
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cells are more sensitive to FasL-mediated killing, even though
XIAP protein levels increase (Schile et al, 2008).
To explorethe role of XIAP E3 activity in type II versus type I
behavior, we transfected OE-Bcl2/DXIAP HCT116 cells with
mCherry-tagged XIAP mutants deleted for the RING domain
(residues 438–497, XIAPDRING) or carrying a mutation in a
highly conserved RING-domain residue (XIAP-H467A; Yang
et al, 2000). We observed that acquisition of a type II
phenotype, in which effector substrate cleavage was blocked
by Bcl2 over-expression, required signiﬁcantly higher concen-
trations of XIAPDRING than full-length XIAP (the effect is
particularly evident at the 24-h time point; Figure 9A; Supple-
mentary Figure S5B). Because XIAP and XIAPDRING were
taggedwithmCherry,itwaspossibletomeasuretheamountof
recombinant protein at a single-cell level and account for
any differences in protein levels; this is important because
RING-domain deletion signiﬁcantly alters XIAP half-life and
expression levels (Schile et al, 2008). Strikingly, the rapid
cleavage of effector caspase substrates observed in OE-Bcl2/
DXIAP HCT116 cells (by live-cell imaging of cells co-
transfected with EC-RP) was disrupted in cells expressing
intermediate amounts of XIAPDRING. In these cells, cleavage
of an EC-RP reporter occurred gradually over a period of
hours (Figure 9B). This phenotype corresponds to neither
type I nor type II behavior but instead to a loss of ‘snap-
action’effectorcaspase activation.The loss ofthis ‘all-or-none’
control was also evident in ﬂow cytometry data: many cells
expressing intermediate level of mCherry-XIAPDRING exhib-
ited partial EC substrate cleavage (Supplementary Figure S5C,
bottom row).
To extend the mapping of phase space to proteins with
mutations that affect reaction rates, we generated a reduced
version of EARM1.4 that focuses on reactions involving XIAP
and caspase-3 (Supplementary Figure S7; Supplementary
Tables SIV–SVI). When the dynamics of effector caspase
substrate cleavage were simulated using the reduced model
assuming either (i) no XIAP, (ii) wild-type XIAP at normal
levels, or (iii) E3 ligase-deﬁcient XIAP (present at wild-type
levels),weobservedagoodmatchtodata.Themodelcorrectly
predicted that when MOMP was blocked (by Bcl2 over-
expression) cleavage of effector caspase substrates should be
rapid and complete in the absence of XIAPand fully blockedin
the presence of wild-type XIAP. However, when the rate
constant for XIAP E3 ligase activity was set to zero (kc8¼0, the
assumed consequence of RING-domain deletion) cleavage
of caspase-3 substrates lost its normal ‘snap-action’ property
at intermediate amounts of XIAP (Figure 9C). To map EC
substrate cleavage dynamics in the two-dimensional phase
space of [caspase-3] versus [XIAP], we computed the duration
of the rise in cEC-S in the presence of full-length or truncated
XIAP. When cells expressed XIAPDRING, but not when they
expressed the full-length protein, we observed a dramatic
increase in the time required for completion of PARP cleavage
near the type I versus type II separatrix (Figure 9D). We
concludethattheRINGdomainofXIAPisindeednecessaryfor
holding caspase-3/7 in an inactive state during the pre-MOMP
delay in type II HCT116 cells. When XIAPDRING is present at
concentrations similar to normal levels of full-length XIAP, a
breakdowninsnap-actioncontrolofeffectorcaspaseactivityis
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Source data is available for this ﬁgure in the Supplementary Information.
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compensate for this defect at least partly, perhaps explaining
the relative normalcy of mice expressing E3 ligase-deﬁcient
XIAP, which is substantially more abundant than wild-type
XIAP (because of the increased stability of XIAP lacking an E3
ligase domain; Schile et al, 2008).
Discussion
In this paper, we study cells undergoing receptor-mediated
apoptosis and ask how MOMP-independent type I and MOMP-
dependent type II phenotypes are controlled. Using a
previouslydevelopedODE-based model of extrinsic apoptosis,
wecomputeDLEsandgenerateamulti-dimensionallandscape
that relates the concentrations of six key regulatory proteins to
the likelihood of type I versus type II phenotypes. We then
measure protein concentrations in tumor cell lines and place
them on the DLE landscape. Each cell line is represented as an
ellipsoid whose midpoint corresponds to the population-
average protein concentration (as determined from calibrated
immunoblots) and whose axial dimensions are determined by
cell-to-cell variation in protein concentrations (as determined
by ﬂowcytometry). We ﬁnd that control over type I and type II
phenotypes is multi-dimensional with a particularly strong
dependence on the ratio of XIAP to pro-caspase-3 concentra-
tions. A separatrix sharply demarcates the two phenotypes in
the [XIAP]:[caspase-3] landscape meaning that a relatively
small change in the ratio of the two proteins can cause a
sudden switch from type I to type II behavior. We have
validated these predictions in three ways. First, we demon-
strate that HCT116 cells, which are exclusively type II but are
predictedtobesensitivetoXIAPlevels,canbeswitchedtotype
I if XIAP is deleted by homologous recombination. Second, we
show that SKW6.4 cells, which are normally type I and are
predicted to be insensitive to XIAP levels, remain type I when
XIAP is over-expressed. Finally, we show that both T47D
breastcancercellsandDXIAPHCT116expressingintermediate
levels of XIAP lie near the separatrix such that some cells in
a population exhibit a type I behavior and others a type II
behavior, a striking example of cell-to-cell variability in
phenotype.
DLE-basedphasediagramspredictthatthe[XIAP]:[caspase-3]
ratio is not the only factor regulating type I versus type II
behavior:thepositionoftheseparatrixinthe[XIAP]:[caspase-3]
plane shifts signiﬁcantly with changes in the concentrations
of ligand, receptor and pro-caspase-8. We test the depen-
dence on ligand concentration experimentally and conﬁrm
that the type I region expands as ligand concentration
increases. Thus, control over extrinsic cell death is multi-
factorial and sensitivity to any single protein concentration
(e.g. [XIAP]) is dependent on the concentrations of
other proteins. Moreover, by analyzing cells in which the
RING domain of XIAP has been deleted or mutated, we
also show that phase space analysis can be extended to
predicting the consequences of altering rate parameters.
The E3 ligase activity of XIAP normally promotes caspase-3
ubiquitylation and consequent proteasome-dependent degra-
dation. Modeling predicts that eliminating this reaction (by
setting rate parameter kc8 to zero in EARM1.4) will prevent
cells from sustaining the pre-MOMP delay characteristic of
type II apoptosis. Experiments conﬁrm this prediction
and reveal that cells expressing XIAPDRING lack normal
‘snap-action’ cleavage of effector caspase substrates. We
propose that DLE-based phase diagrams represent a methodo-
logy for studying multi-factorial control over cell fate
in a rational and systematic manner. In the current work,
this approach allows us to reconcile a literature that ﬁnds
XIAP and its E3 ligase activity to be either critical or irrelevant
in the control of extrinsic apoptosis, depending on the
experimental setting and cell type under study (Deveraux
et al, 1997; Harlin et al, 2001; Bratton et al, 2002; MacFarlane
et al, 2002; Sun et al, 2002; Cummins et al, 2004; Silke et al,
2005; Eckelman et al, 2006; Rehm et al, 2006; Schile et al,
2008). The strong context dependence of these XIAP pheno-
types is explained (at least in principle) by the impact of other
cellular factors known to vary signiﬁcantly from one cell type
to the next, such as caspase-3 levels, and by experimental
variables, such as ligand dose and potency.
A key feature of DLE-based phase diagrams is that they
reveal the dynamical consequences of variation in protein
concentration that exists prior to treatment of cells with death
ligand. In contrast to bifurcation analysis of steady states,
computing DLEs maps phenotypes onto transient signals,
which is important for a system in which steady states are not
reached on any meaningful timescale (except when apoptosis
pathways are inactive in cells not exposed to ligand). The
ranges of protein concentrations over which DLEs are
computed are derived from data from real cells in their natural
states or following gene deletion and over-expression. Predic-
tions then cover meaningful biological variation, and DLE
phase diagrams allow us to determine when cell-to-cell
variation in protein levels will be consequential. Because
the process of gene expression and protein translation
are inherently noisy (Lestas et al, 2010) even genomically
identical cells exhibit variability in protein expression levels.
Forcellsthatmapclosetoaseparatrix,thisinherentvariability
will lead to heterogeneous phenotypes. Cell lines that lie
further from a separatrix are likely to behave more homo-
genously, as observed for SKW6.4 and parental HCT116 cells.
In the future, it should be possible to extend the approach of
mapping cell-to-cell variation onto phase diagrams to other
forms of programmed cell death, such as autophagy and
necroptosis.
Insight into the regulation of type I and type II cell
death phenotypes in human cells
With regard to the regulation of type I and type II apoptosis
phenotypes in human cells,ourdata support fourconclusions.
First, they demonstrate that deletion of XIAP in type II cells
causes them to behave astype I cells while retainingthe ability
to rapidly and completely activate effector caspases when
exposed to death ligands. Jost et al (2009) have observed a
similar phenomenon in the livers of Bid
 /  XIAP
 /  mice by
showing that hepatocytes switch from a type II to a type I
phenotype. We predict that a key factor in the switch is the
[XIAP]:[caspase-3] ratio: when it is low, type I behavior
predominatesandwhenitishigh,typeIIbehaviorisprevalent.
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altogether.
We ﬁnd no evidence that the levels of caspase-8/10 required
to trigger apoptosis in parental and DXIAP HCT116 differ; both
ﬂow cytometry and live-cell imaging data suggest that all
four HCT116-derived cell lines have similar initiator caspase
activation levels and dynamics (Figure 4A; Supplementary
Figure S2B). This leads us to speculate that, at least under
our conditions, MOMP functions as a gatekeeper for acti-
vation of effector caspases rather than as an ampliﬁer of
initiator caspase; enhanced cleavage of pro-caspase-3 (e.g. by
caspase-9) does not appear to be critical. Low [XIAP] and/or
high [caspase-3] make MOMP unnecessary in type I cells,
and cleavage of pro-caspase-3/7 by caspase-8/10 is sufﬁcient
to induce death. In type II HCT116 cells, by contrast, the
key role of MOMP in extrinsic apoptosis is to cause
Smac-dependent inhibition of XIAP. Consistent with this,
Wilson et al (2009) recently showed that RNAi-mediated
depletion of Smac but not caspase-9 (which is activated by
cytochrome c released during MOMP) blocks apoptosis in
HCT116 cells treated with anti-Fas antibody or TRAIL.
Similarly, Shawgo et al (2009) showed that, following
treatment with anti-Fas antibody, type II Jurkat cells do not
require activation of caspase-9 by the apoptosome to die. We
conclude that HCT116 cells can accumulate sufﬁcient ‘latent’
caspase-3/7 an hour or so after TRAIL exposure to die via a
direct,typeImechanism,butthatXIAPimposesablockonthis
latent activity that must be relieved by MOMP, thereby
enforcing type II behavior.
Second, we show that type I and type II phenotypes can
co-exist within a cell population. The two phenotypes have
hitherto been regarded as fundamentally distinct with type I
behavior predominating in mesenchymal-like cells and type II
behavior in epithelial-like cells (Algeciras-Schimnich et al,
2003). Indeed, all SKW6.4 cells are type I whereas all HCT116
cells are type II. However, in lines such as T47D or HCT116
expressing intermediate levels of XIAP, some cells are type I
and othersare type II. The relative frequencyof type I and type
IIphenotypes isdetermined by theligand dose, aspredicted by
simulation and consistent with previously reported but
unexplained observations (Rudner et al, 2005). This pheno-
typic variability presumably arises from natural variation in
the levels of proteins such as caspase-3 and XIAP. We and
othershaverecentlyshownsuchvariationtohaveasigniﬁcant
impact on how rapidly cells die (Rehm et al, 2009; Spencer
et al, 2009) and modeling suggests that measured variation
in protein levels is sufﬁcient for cell lines to straddle the
separatrix in the [XIAP] versus [caspase-3] phase space. Our
ﬁndings may also explain why XIAP-null mice have few
obvious defects (Harlin et al, 2001; Cummins et al, 2004):
in the absence of XIAP, cells may simply alter the balance
between type I and type II phenotypes.
Third, we predict and demonstrate experimentally that the
E3 ubiquitin ligase domain of XIAP is necessary for effector
caspase activity to be restrained prior to MOMP during
extrinsic cell death. In the absence of this domain, effector
caspase processing is gradual and normal snap-action clea-
vage of effector caspase substrates is not observed. We have
previously observed fractional PARP cleavage and a ‘half-
dead’ state in OE-Bcl2 HeLa cells in which XIAP levels were
reduced with anti-XIAP siRNA or proteasome activity blocked
with drugs (Albeck et al, 2008a). These data suggest that
inhibition of MOMP in XIAPDRING mice (Schile et al, 2008),
by Bid deletion or Bcl2 over-expression for example, might
generate a much stronger phenotype than either Bid deletion
or Bcl2 over-expression, or XIAPDRING mutation alone.
XIAPDRING cells require MOMP to promote snap-action
effector caspase dynamics and therefore a state of partial
activation could arise when MOMP is blocked in these cells.
Partialeffectorcaspaseactivationmaybetumorigenicinvivoif
caspase-activated DNases damage the genome (Vaughan et al,
2002, 2005; Lovric and Hawkins, 2010). More generally, these
data highlight that the ability of XIAP to inhibit caspase-3
activity in two distinct ways—competitive inhibition and
degradation—is important for its function. Protein degrada-
tion may play a key role in regulating the activation kinetics in
other cell processes as competitive inhibition alone is likely to
beinsufﬁcienttocompletelyinactivatemanyenzymes(Albeck
et al, 2008b).
Fourth, we demonstrate the utility of phase diagrams as a
means to understand and predict how different cell types
respond to death ligand. From these diagrams, it is clear that
controlover type I versus II behavior is multi-factorial with the
‘downstream’ proteins caspase-3 and XIAP playing the
primary role in our studies. In contrast, elegant work by Peter
and colleagues has shown ‘upstream’ events such as the
efﬁciency of DISC assembly to be determinative of type I
versus type II phenotypes in other contexts (Scafﬁdi et al,
1998; Barnhart et al, 2003). Such apparent discrepancies are
common in the study of complex regulatory pathways but
Figure 9 Deletion of the XIAP RING domain disrupts the dynamics of effector caspase activation. (A) EC substrate cleavage in OE-Bcl2/XIAP HCT116. Cell death
(percentage positive) inTRAIL-treated OE-Bcl2/DXIAP HCT116 cells expressing mCherry alone (CHY;dark gray), mCherry fused to full-length XIAP (CHY-XIAP; blue),
ormCherryfusedtoanXIAPtruncationlackingtheRINGdomain(excludingresidues437–497,CHY-XIAPDRING;red).UntreatedmCherry-transfected cellsareshown
in light gray (CHY (NT)). EC substrate cleavage and CHY protein intensity (594nm ﬂuorescence) were measured by ﬂow cytometry (representative raw data are shown
inSupplementaryFigureS6C).AverageendogenousXIAPlevelisdenotedwithanarrowandtheresponsesofuntransfectedcellsindicatedwithasterisks.Asdiscussed
inthe text, transfection itself sensitizes cells HCT116 cells to TRAIL, and it is therefore necessary to compare the red and blue data to the control data inlight gray. Error
bars report the standard deviation of biological triplicates from one representative experiment. (B, C) Dynamics of EC-RP cleavage as determined by live-cell
microscopy(B)andpredictedbysimulation(C)forTRAIL-treatedOE-Bcl2/DXIAPHCT116cellstransfectedwithmCherryalone(CHY;left),mCherryfusedtofull-length
XIAP(CHY-XIAP;center),ormCherryfusedtoaRING-domaindeletionmutantofXIAP(CHY-XIAPDRING;right).ThelevelofmCherryﬂuorescenceisreportedusinga
scalefromyellowtogreen,asindicated.(D)SimulateddurationofcleavedECsubstrateriseinOE-Bcl2/XIAPHCT116.2Dphasespacemapsshowinghowtheduration
of the rise in cleaved EC substrate for wild-type XIAP (left) and XIAPDRING (right) is dependent on the concentration of the XIAP and caspase-3 species in model
simulations.ForXIAPDRING,therateparameterforXIAPE3ligaseactivitytowarditscaspase-3substrate issettozero.Blacklinesrepresentthedemarcationbetween
type I versus II phenotypes as determined by fraction of cleaved EC substrate in these simulations, with type I cells mapping above and type II cells below
(Supplementary Figure S8). Source data is available for this ﬁgure in the Supplementary Information.
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providing predictive insight into multi-factorial control me-
chanisms. Providing a platform to reconcile discrepancies is
particularlyrelevantbecausepublishedstudiesuseavarietyof
cell lines and ligands. Our ﬁndings do not contradict previous
conclusions (Scafﬁdi et al, 1998; Barnhart et al, 2003); we
simply explore a different region of phase space. The most
interesting regions in this space lie along separatrices that
divide cells into fundamentally different types. We have
investigated some dimensions of this separatrix but we
presume that other dimensions (such as FLIP levels (Scafﬁdi
et al, 1999b; Lavrik et al, 2007; Wilson et al, 2009) or ligand
andreceptormultimerization(Scafﬁdietal,1999a;Siegeletal,
2004)) will also be important for understanding the control of
type I versus II phenotypes. Moreover, it should also be noted
that the computational and experimental analysis in the
current paper follows the common practice of using Bcl2
over-expression to assay for type I death (a practice similar to
using Bid
 /  mice; Jost et al, 2009). However, our immuno-
ﬂuorescence data suggest that Bcl2 levels can also alter the
fraction of cells that use MOMP in response to death ligand.
Understanding in detail the ﬂux through the caspase cascade
and MOMP pathways in type I cells where MOMP is not
inhibited will require further investigation. Development of
moreefﬁcientsoftwareshouldmakeitfeasibletocomputeand
validateseparatricesfoundinthefullmulti-dimensionalphase
space of extrinsic apoptosis. We also anticipate that the DLE
methodology can be made more ﬂexible by developing
interactive software tools that enable normalization across
several parameters, computation of the multi-dimensional
difference betweenmodel trajectories using a subset of protein
species, and modulation of speciﬁc rate parameters. However,
more precise and detailed underlying models are required
before we can study processes such as ligand or receptor
oligomerization computationally (Scafﬁdi et al, 1998; Schmitz
etal,1999; Algeciras-Schimnich etal,2003; Rudneretal,2005;
Lee et al, 2006).
Summary
Lyapunov exponent analysis has allowed us to generate a
contextualized view of the regulation of type I versus type II
behavior in apoptosis: multi-dimensional cell fate maps
predict the behavior of multiple cell lines over multiple doses
of death ligand and several changes in protein expression
levels. The XIAP RING deletion examined here is an unusual
mutation in that it completely eliminates one of the two
reactions in which XIAP participates; most naturally occurring
mutations have more subtle effects on reaction rates.
Improved software and models should make it possible to
analyze more subtlephenotypic changes associated with point
mutations. Ultimately, we expect experimental validation of
other dimensions in phase space to reconcile further dis-
cordant observations from the literature thereby generating a
sound and predictive understanding of type I versus II control.
Signaling phase diagrams based on computation and experi-
ment hold promise as biochemical analogs of the classic
polygenic models of Yule (1906) and Fisher (1918), which
were developed to explain quantitative control of traits by
multiple genes.
Materials and methods
Cell line derivation and maintenance
Parental and DXIAP HCT116 cells were obtained from BVogelstein and
F Bunz (Cummins et al, 2004). Parental and DXIAP HCT116 cells were
maintained in McCoy’s 5A media supplemented with 50units/ml
penicillin/streptomycin, 2mM L-glutamine (Invitrogen), and 10%
bovine calf serum (Hyclone) and SKW6.4 and T47D cells (ATCC) were
maintained in RPMI supplemented with 50units/ml penicillin/strep-
tomycin, 2mM L-glutamine (Invitrogen), and 10% bovine calf serum
(Hyclone). OE-Bcl2 derivative cell lines were generated using a
retrovirus produced by co-transfection of 293T cells (ATCC) with
pCL-ampho and pBabe-Bcl2 (a gift from J Brugge). Stable OE-Bcl2 and
OE-Bcl2/DXIAP HCT116 cells were selected with 5mg/ml of puromy-
cin, and stable OE-Bcl2 SKW6.4 and T47D cells were selected
with 1mg/ml and 2mg/ml puromycin, respectively. Following selec-
tion, experiments were performedin clones forstable OE-Bcl2 and OE-
Bcl2/DXIAP HCT116 cells and pools for stable OE-Bcl2 SKW6.4 and
T47D cells.
Expression constructs
cDNAs coding for mCherry and for mCherry fused to full-length XIAP,
XIAP with a RING-domain deletion, and XIAP with a RING-domain
point mutation (CHY, CHY-XIAP, CHY-XIAPDRING, and CHY-XIAP-
H467A, respectively) were ampliﬁed by PCR (TaqPlus Precision PCR
System, Stratagene), cloned in pExchange-1 (Stratagene) and se-
quence veriﬁed. CHY was ampliﬁed using forward primer (50-
CGCGCGGATCCGCCGCCATGGTGAGCAAGGGCGAGGAGGATAACATG
GCC-30) and reverse primer (50-CCGCCGGAATTCTTACTTGTACAG
CTCGTCCATGCCGCCGGTGGAGTGGCGGCCC-30) and cloned in the
BamHI and EcoRI sites to generate a vector to express CHYalone, or
forward primer (50-GCGGCGGCCGCGCCGCCATGGTGAGCAAGGGC
GAGGAGGATAACATGGCC-30) and reverse primer (50-GCGGGATCCG
CCGCCATGGTGAGCAAGGGCGAGGAGGATAACATGGCC-30) and
cloned in NotI and BamHI sites to generate a vector to express fusion
proteins. XIAP, XIAPDRING, and XIAP-H467A were ampliﬁed from
pEBB-XIAP or pEBB-XIAPH467 obtained from Jon Ashwell (via
Addgene.org), using forward primer (50-GGCCGGATCCGCCGCCAT
GACTTTTAACAGTTTTGAAGGATCTAAAACTTGTGTACCTGC-30), and
reverse primer (50-CCGCCGGAATTCTTACTTGTACAGCTCGTCCATG
CCGCCGGTGGAGTGGCGGCCC-30) for XIAP and XIAPH467 or reverse
primer (50-GGCCGAATTCTTAAGTACTAATCTCTTTCTGTAATGAAGTC
TGACTTGACTC-30) for XIAPDRING (excluding residues 437–497).
These PCR products were cloned in the BamHI and EcoRI sites of
pExchange-1-CHY. Construction and use of the IC- and EC-FRET
reporters (IC-RP and EC-RP) was previously described (Albeck et al,
2008a).
Cell treatments
TRAIL (SuperKiller TRAIL, Alexis Biochemicals) TNF (PeproTech),
or FasL (SuperFasL Alexis Biochemicals) and CHX (Sigma-Aldrich)
were added to cells in 1/20 of the culture volume at the indicated
ﬁnal concentrations. For treatment with death ligands, HCT116-
derived cell lines were plated at 4 10
4cells/cm
2 1 day before
treatment, T47D cells were also plated at 4 10
4cells/cm
2 2 days
before treatment and SKW6.4 cells were plated at 4 10
5cells/ml on
the day of treatment.
FortransienttransfectionwithCHY-fusionswithorwithoutIC-RPor
EC-RP, HCT116-derived cell lines were plated at 4 10
4cells/cm
2 2
days before treatment and transfected using Lipofectamine 2000
(Invitrogen) as per the manufacturer’s recommendation 1 day before
treatment. For transiently transfected cells, stimulus was added by
changing the medium at the beginning of treatment.
SKW6.4-derived cell lines were transfected by electroporation
(1 10
6cells and 10mg plasmid DNA in 400ml, 950mF, 250mV with
the GenePulserII (Bio-Rad)) 2 days prior to treatment and plated at
4 10
5cells/ml before adding stimulus in 1/20 of the culture volume
treatment.
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caspase activity and distributions of protein levels
Preceding treatment (for distributions of protein levels) or following
treatment (for assays of initiator and effector caspase activation),
ﬂoating cells were collected and mixed with the trypsinized adherent
cells before ﬁxation in 4% paraformaldehyde in PBS, followed by
permeabilization in 100% methanol. The cells were stored in methanol
at  201C for up toaweek. Cells werewashedwithPBS þ 0.1% Tween-
20andstainedfor1hwithprimaryantibodies.FollowingwashesinPBS
þ 0.1% Tween-20, cells were stained for 1h with secondary antibodies
if warranted. For assays of initiator and effector caspase activation cells
were stained with custom Alexa Fluor 488-conjugated anti-cPARP
(Asp214) monoclonal antibody (1:100 BD624020; BD Biosciences) for
effector caspase activity measurements and PE-conjugated anti-cleaved
caspase-3 antibody (1:100 BD550914; BD Biosciences) for initiator
caspase activity measurements, and where indicated, with Alexa Fluor
405-conjugated mouse anti-Bcl2 (1:25 SC7382; Santa Cruz Biotechnol-
ogies). Note that because of the nature of the targeted epitopes, anti-
cPARPand anti-cleaved caspase-3 antibodies recognize cleaved caspase
substrates other than PARPor caspase-3, and we therefore refer to these
as measures of ‘cleaved EC substrate’ and ‘cleaved IC susbstrate,’
respectively (cEC-S and cIC-S). For all ﬂow cytometry experiments,
single antibody stained controls were used for compensation. For
distributions of protein levels, cells were stained with Alexa-647-
conjugated a-XIAP clone 28 (610717; BD Biosciences) or Alexa-488-
conjugated a-C3 (SC7272; Santa Cruz Biotechnology) before ﬁnal
washes and resuspension in PBSþ0.1% Tween-20. All antibody
dilutions were made in PBSþ0.1% Tween-20þ1% bovine serum
albumin. Flow cytometry analysis was performed using the High
Throughput Sampler on a BD LSRII instrument (BD Biosciences). Data
were analyzed using FlowJo 8.8 (TreeStar) and custom software in
MATLAB (The MathWorks).
Clonogenic assays
For clonogenic assays, HCT116-, T47D-, and SKW6.4-derived cells
were treated in biological triplicates for 6h with or without 2.5mg/ml
CHX alone and with or without 50ng/ml TRAILþ2.5mg/ml CHX as
described above. After treatment, the cells were diluted in their
respectiveculturemedium(aminimumof2400-fold).HCT116-derived
lines were plated at B300cells/6cm dish, and colonies were counted
after 12 days, T47D-derived lines were plated at B600cells/6cm dish,
and colonies counted at 20 days. SKW6.4-derived lines were plated at
B2cells/wellinone96-wellplateforeachsampleandgrowth-positive
wells were counted after 21 days. For TRAILþCHX treatment, we
report the relative average number of colonies from biological
triplicate samples, normalized by the average number of colonies
obtained from the triplicate CHX alone samples. For TRAIL-only
treatments, we normalized by the average number of colonies
obtained from the triplicate mock-treated cells.
Live-cell imaging and image processing
Cells were imaged on a DeltaVision microscope (Applied Precision
Inc.) at 3-min intervals, under B5% CO2 at 371C. Time-lapse imaging
data of IC-RP- or EC-RP-transfected cells were preprocessed in ImageJ
to generate a mask and cells were then tracked by custom software in
MATLAB (Jaqaman et al, 2008) that was reparameterized for HCT116
cells. Post-processing of the data was performed in MATLAB (The
MathWorks). OE-Bcl2 SKW6.4 cells were seeded centrifuging onto
Cell-Tak (BDBiosciences)coated chamberslides18h priorto imaging.
Fixed-cell imaging
Following plating and treatment in 96-well optical plates, cells were
ﬁxedin4%paraformaldehydeinPBS,followedbypermeabilizationin
100% methanol. Cells were incubated in Odyssey Blocking Buffer
(Licor) for 1h at room temperature, then stained overnight at 41C with
FITC-conjugated anti-cleaved caspase-3 (1:25 BD559341; BD Bios-
ciences),AlexaFluor 647-conjugatedanti-cPARP (1:250BD558710;BD
Biosciences)andAlexaFluor 555-conjugatedanti-cytochromec(1:250
BD558700; BD Biosciences) in PBSþ0.1% Tween-20þ1% bovine
serum albumin. After washing with PBSþ0.1% Tween-20, cells were
stained with Hoechst 33352 (4mM; Invitrogen) and Whole Cell Blue
dye (1:1000; Cellomics). To insure that all cells—including apoptotic
cells—were visualized, the cells were centrifuged at every step (4min
at 1000g). Images were obtained on a CellWorX station and a
DeltaVision microscope (Applied Precision Inc.). The number of cells
counted per well for each cell line was as follows: HCT116 (384, 175,
416), OE-Bcl2/DXIAP HCT116 (350, 236, 244), DXIAP HCT116 (174,
341, 225), T47D (608, 576, 691), and OE-Bcl2 T47D (157, 172, 221,
187, 214).
Immunoblots
For immunoblot analysis, cells were lysed in sample buffer (112.5mM
Tris–Cl, pH 7.5, 4% SDS, 1mg/ml leupeptin, 1mg/ml pepstatin, and
1mg/ml chymostatin) to generate whole-cell homogenates. Total
protein concentration was determined using the bicinchoninic acid
assay (Pierce). Equal amounts of lysates were run on 8% Tricine
SDS–PAGE gels, and transferred to nitrocellulose. Membranes were
incubated 1h at room temperature in Odyssey Blocking Buffer (Licor)
then probed with mouse monoclonal anti-caspase-8 (1:1000 clone
1C12 CST9746), rabbit polyclonal anti-caspase-6 (1:500 CST9762),
rabbit polyclonal anti-PARP (1:500 CST9542), rabbit polyclonal anti-
Bcl-xl (1:250 CST2762) (Cell Signaling Technologies), mouse mono-
clonal anti-caspase-3 (1:250 SC7272), mouse monoclonal anti-Bcl2
(1:100 SC7382), rabbit polyclonal anti-Bax (1:200 SC483), rabbit
polyclonal anti-Mcl1 (1:200 SC819) (Santa Cruz Biotechnology),
mouse monoclonal anti-XIAP (1:500 clone 28; BD610716; BD
Biosciences), rabbit polyclonal anti-Smac (1:500 567365; Calbio-
chem), rat polyclonal anti-FLIP (1:1000; Alexis Biosciences), or rabbit
polyclonal anti-Bid (1:250 HPA000722; Atlas Antibodies) overnight at
41C. After washing, the antigen–antibody complexes were detected
with IRDye800-conjugated donkey anti-mouse or anti-rabbit second-
ary antibodies as appropriate (1:5000, 610-732-124, and 612-732-120;
Rockland Immunochemicals). Fluorescence was assessed on an
Odyssey Scanner (Licor) and images were analyzed using the Odyssey
software (Licor).
Physicochemical modeling of the apoptosis
pathway
The apoptosis signaling model was built and run in MATLAB 2007b
using the ode15s solver. This model is a variant of a published model
(Albeck et al, 2008b) and includes the major features of both the direct
and mitochondrial pathways downstream of death receptor activation
(see Supplementary Methods and Supplementary Table SI for details).
The model was reparameterized from the version published for HeLa
cells (Albecket al,2008b) toparametersbettersuited for HCT116cells,
as described in Supplementary Tables SI–SIII and Box 1. The reduced
model used for the analysis of E3 ligase-deﬁcient XIAP focuses on the
interactions between caspase-3 and XIAPand is parametrized with the
samereactionratesasEARM1.4,asdescribedinSupplementaryFigure
S7 and Supplementary Tables SIV–SVI.
DLE computation
TheDLEanalysiswasperformedasdescribedinAldridgeetal(2006a),
with the phase space region searched limited to caspase-3, caspase-8,
caspase-6, ligand, receptor, XIAP, and EC substrate. Bcl2 over-
expression conditions were used (10 , sufﬁcient to block MOMP)
and initial conditions were sampled evenly from the following ranges:
caspase-3(1 10
3–1 10
6molecules/cell sampledlinearlywith 50 and
20concentrationsinFigures1Band7AandinFigure8A,respectively),
XIAP (0–6 10
4molecules/cell sampled linearly with 50 and 20
concentrations in Figures 1B and 7A and in Figure 8A, respectively),
caspase-6 (0–2 10
4molecules/cell sampled linearly with 50 and 20
concentrations in Figures 1B and 8A, respectively), caspase-8 (1500–
8500 sampled linearly with eight concentrations), ligand (1.6, 40,
1 10
3, 2.5 10
4, and 1 10
5a.u. where 1 10
3 is equivalent to
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3,5 10
4,
and 5 10
5molecules/cell). Initial concentrations used for the EC
substrate PARP were 1000000 and 1000001molecules/cell; this
nominal range allowed us to include EC substrate cleavage as a
readout for apoptosis in the DLE calculation without having the EC
substrate concentration affect the value of the DLE across those two
conditions. The baseline phase space slice through XIAPand caspase-
3, unless otherwise noted, is 1 10
4molecules/cell for caspase-6,
3500molecules/cell for caspase-8, 1 10
3a.u. for ligand (for 50ng/ml
of TRAIL), 5 10
3molecules/cell for receptor. The simulations and
DLEs were computed in MATLAB 2007b (The MathWorks) and were
visualized in Spotﬁre software. The simulation and DLE computation
code is available in the Supplementary Materials.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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